Oral anticoagulants for the treatment of venous thromboembolism and non-valvular atrial fibrillation: a cost analysis

Objective: To analyze the total direct cost of anticoagulant therapies indicated for the chronic treatment of patients with non-valvular atrial fibrillation (AF) and the acute treatment of venous thromboembolism (VTE) in the perspective of a tertiary teaching hospital and the national public health...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Isabella C DENARDIN, Helena H. BORBA, Antonio M. MENDES
Formato:	article
Lenguaje:	EN PT
Publicado:	Sociedade Brasileira de Farmácia Hospitalar e Serviços de Saúde 2021
Materias:	Public aspects of medicine RA1-1270 Pharmacy and materia medica RS1-441 Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/166e9290e0ee4250a16d5ef8c03ef9d5
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:166e9290e0ee4250a16d5ef8c03ef9d5
record_format	dspace
spelling	oai:doaj.org-article:166e9290e0ee4250a16d5ef8c03ef9d52021-11-28T02:43:59ZOral anticoagulants for the treatment of venous thromboembolism and non-valvular atrial fibrillation: a cost analysis10.30968/rbfhss.2021.121.05922179-59242316-7750https://doaj.org/article/166e9290e0ee4250a16d5ef8c03ef9d52021-03-01T00:00:00Zhttps://www.rbfhss.org.br/sbrafh/article/view/592https://doaj.org/toc/2179-5924https://doaj.org/toc/2316-7750 Objective: To analyze the total direct cost of anticoagulant therapies indicated for the chronic treatment of patients with non-valvular atrial fibrillation (AF) and the acute treatment of venous thromboembolism (VTE) in the perspective of a tertiary teaching hospital and the national public health system. Methods: Therefore, the review of the treatment regimens that included all the oral anticoagulants based on nationals and internationals guidelines. The cost data were extracted and performed the simulation of the costs of pharmacological therapy and exams for monitoring therapeutic goals. The time horizon was defined by 365 days for AF and 90 days for TEV. Results: The treatment cost of 90 days in VTE was: rivaroxaban (USD $82,96 to USD $156,15), apixaban (USD $110,25 to USD $123,11), edoxaban (USD $106,56 to USD $265,15), dabigatran (USD $150,71 to USD $249,98) and warfarin (USD $54,94 to USD $159,66). While the treatment cost of AF was: rivaroxaban (USD $270,35 to USD $508,89), apixaban (USD $414,86 to USD $463,26), edoxaban (USD $402,41 to USD $477,78), dabigatran (USD $414,86 to USD $416,24) and warfarin (USD $20,03 to USD $43,54). Conclusion: Warfarin presented the lowest treatment cost for both comorbidities. However, although direct oral anticoagulants (DOACs) are always associated with higher price ranges, were observed price ranges in VTE treatment where DOACs proved to be economically more advantageous than warfarin, still requiring complete economic assessments. Isabella C DENARDIN Helena H. BORBA Antonio M. MENDES Sociedade Brasileira de Farmácia Hospitalar e Serviços de SaúdearticlePublic aspects of medicineRA1-1270Pharmacy and materia medicaRS1-441Therapeutics. PharmacologyRM1-950ENPTRevista Brasileira de Farmácia Hospitalar e Serviços de Saúde, Vol 12, Iss 1 (2021)
institution	DOAJ
collection	DOAJ
language	EN PT
topic	Public aspects of medicine RA1-1270 Pharmacy and materia medica RS1-441 Therapeutics. Pharmacology RM1-950
spellingShingle	Public aspects of medicine RA1-1270 Pharmacy and materia medica RS1-441 Therapeutics. Pharmacology RM1-950 Isabella C DENARDIN Helena H. BORBA Antonio M. MENDES Oral anticoagulants for the treatment of venous thromboembolism and non-valvular atrial fibrillation: a cost analysis
description	Objective: To analyze the total direct cost of anticoagulant therapies indicated for the chronic treatment of patients with non-valvular atrial fibrillation (AF) and the acute treatment of venous thromboembolism (VTE) in the perspective of a tertiary teaching hospital and the national public health system. Methods: Therefore, the review of the treatment regimens that included all the oral anticoagulants based on nationals and internationals guidelines. The cost data were extracted and performed the simulation of the costs of pharmacological therapy and exams for monitoring therapeutic goals. The time horizon was defined by 365 days for AF and 90 days for TEV. Results: The treatment cost of 90 days in VTE was: rivaroxaban (USD $82,96 to USD $156,15), apixaban (USD $110,25 to USD $123,11), edoxaban (USD $106,56 to USD $265,15), dabigatran (USD $150,71 to USD $249,98) and warfarin (USD $54,94 to USD $159,66). While the treatment cost of AF was: rivaroxaban (USD $270,35 to USD $508,89), apixaban (USD $414,86 to USD $463,26), edoxaban (USD $402,41 to USD $477,78), dabigatran (USD $414,86 to USD $416,24) and warfarin (USD $20,03 to USD $43,54). Conclusion: Warfarin presented the lowest treatment cost for both comorbidities. However, although direct oral anticoagulants (DOACs) are always associated with higher price ranges, were observed price ranges in VTE treatment where DOACs proved to be economically more advantageous than warfarin, still requiring complete economic assessments.
format	article
author	Isabella C DENARDIN Helena H. BORBA Antonio M. MENDES
author_facet	Isabella C DENARDIN Helena H. BORBA Antonio M. MENDES
author_sort	Isabella C DENARDIN
title	Oral anticoagulants for the treatment of venous thromboembolism and non-valvular atrial fibrillation: a cost analysis
title_short	Oral anticoagulants for the treatment of venous thromboembolism and non-valvular atrial fibrillation: a cost analysis
title_full	Oral anticoagulants for the treatment of venous thromboembolism and non-valvular atrial fibrillation: a cost analysis
title_fullStr	Oral anticoagulants for the treatment of venous thromboembolism and non-valvular atrial fibrillation: a cost analysis
title_full_unstemmed	Oral anticoagulants for the treatment of venous thromboembolism and non-valvular atrial fibrillation: a cost analysis
title_sort	oral anticoagulants for the treatment of venous thromboembolism and non-valvular atrial fibrillation: a cost analysis
publisher	Sociedade Brasileira de Farmácia Hospitalar e Serviços de Saúde
publishDate	2021
url	https://doaj.org/article/166e9290e0ee4250a16d5ef8c03ef9d5
work_keys_str_mv	AT isabellacdenardin oralanticoagulantsforthetreatmentofvenousthromboembolismandnonvalvularatrialfibrillationacostanalysis AT helenahborba oralanticoagulantsforthetreatmentofvenousthromboembolismandnonvalvularatrialfibrillationacostanalysis AT antoniommendes oralanticoagulantsforthetreatmentofvenousthromboembolismandnonvalvularatrialfibrillationacostanalysis
_version_	1718408422464946176

Oral anticoagulants for the treatment of venous thromboembolism and non-valvular atrial fibrillation: a cost analysis

Ejemplares similares